Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases

Ileana S. Mauldin, Nolan A. Wages, Anne M. Stowman, Ena Wang, Walter C. Olson, Donna H. Deacon, Kelly T. Smith, Nadedja Galeassi, Jessica E. Teague, Mark E. Smolkin, Kimberly A. Chianese‐Bullock, Rachael A. Clark, Gina R. Petroni, Francesco M. Marincola, David W. Mullins, Craig L. Slingluff

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Introduction: Infiltration of cancers by T cells is associated with improved patient survival and response to immune therapies; however, optimal approaches to induce T cell infiltration of tumors are not known. This study was designed to assess whether topical treatment of melanoma metastases with the TLR7 agonist imiquimod plus administration of a multipeptide cancer vaccine will improve immune cell infiltration of melanoma metastases. Patients and methods: Eligible patients were immunized with a vaccine comprised of 12 melanoma peptides and a tetanus toxoid-derived helper peptide, and imiquimod was applied topically to metastatic tumors daily. Adverse events were recorded, and effects on the tumor microenvironment were evaluated from sequential tumor biopsies. T cell responses were assessed by IFNγ ELIspot assay and T cell tetramer staining. Patient tumors were evaluated for immune cell infiltration, cytokine and chemokine production, and gene expression. Results and conclusions: Four eligible patients were enrolled, and administration of imiquimod and vaccination were well tolerated. Circulating T cell responses to the vaccine was detected by ex vivo ELIspot assay in 3 of 4 patients. Treatment of metastases with imiquimod induced immune cell infiltration and favorable gene signatures in the patients with circulating T cell responses. This study supports further study of topical imiquimod combined with vaccines or other immune therapies for the treatment of melanoma.

Original languageEnglish
Pages (from-to)1201-1212
Number of pages12
JournalCancer Immunology, Immunotherapy
Volume65
Issue number10
DOIs
Publication statusPublished - 1 Oct 2016

    Fingerprint

Keywords

  • Cytotoxic T lymphocytes
  • Human
  • Immunotherapy
  • Melanoma
  • TLR agonists
  • Tumor vaccines

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology
  • Cancer Research

Cite this

Mauldin, I. S., Wages, N. A., Stowman, A. M., Wang, E., Olson, W. C., Deacon, D. H., Smith, K. T., Galeassi, N., Teague, J. E., Smolkin, M. E., Chianese‐Bullock, K. A., Clark, R. A., Petroni, G. R., Marincola, F. M., Mullins, D. W., & Slingluff, C. L. (2016). Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases. Cancer Immunology, Immunotherapy, 65(10), 1201-1212. https://doi.org/10.1007/s00262-016-1880-z